Crystalline citalopram diol intermediate alkali

Details Crystalline citalopram diol intermediate alkali Crystalline citalopram diol intermediate alkali

2004-12-06

2008-10-14

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C549S471000, C549S469000

Reexamination Certificate

active

07435838

ABSTRACT:
The present invention relates to the diol intermediate of citalopram useful for treatment of depression, which is the crystal of free base of 3-hydroxylmethyl-4-[1-(4-fluorophenyl)-1-hydroxyl-4-(dimethylamino)]butylbenzonitrile and the method of crystallization thereof. The present invention has disclosed the method to prepare pure citalopram and its purified salts through crystallization of the described base; the optical resolution method of citalopram diol intermediate, the method to prepare S-citalopram and its purified salts by crystals mentioned above. The present invention has also disclosed the method to prepare citalopram and its purified salts, S-citalopram and its purified salts, as well as pharmaceutical formulation thereof obtained. Using methods of the present invention, the quality and yield of the product can be significantly improved, and the production cost of the medicinal material can be reduced.

REFERENCES:
patent: 4136193 (1979-01-01), Bogeso et al.
patent: 4560884 (1985-12-01), Whittecar
patent: 4650884 (1987-03-01), Bogeso
patent: 4943590 (1990-07-01), Boegesoe et al.
patent: 4945590 (1990-08-01), Ogura
patent: 6258842 (2001-07-01), Petersen et al.
patent: 6291689 (2001-09-01), Petersen et al.
patent: 6365747 (2002-04-01), Dall'Asta et al.
patent: 1339435 (2002-03-01), None
patent: 1339436 (2002-03-01), None
patent: 1366525 (2002-08-01), None
patent: 1366526 (2002-08-01), None
patent: 1404475 (2003-03-01), None
patent: 1406236 (2003-03-01), None
patent: 1418205 (2003-05-01), None
patent: 1423644 (2003-06-01), None
patent: 1492861 (2004-04-01), None
patent: 1496358 (2004-05-01), None
patent: 1510024 (2004-07-01), None
patent: 2657271 (1978-03-01), None
patent: 2356199 (2001-05-01), None
patent: 2357762 (2001-07-01), None
patent: WO 98/19511 (1998-05-01), None
patent: WO 98/19512 (1998-05-01), None
patent: WO 00/12044 (2000-03-01), None
patent: WO 03/000672 (2003-01-01), None
patent: WO03000672 (2003-01-01), None
patent: WO03051861 (2003-06-01), None
patent: WO 03/072565 (2003-09-01), None
patent: WO 2004/056754 (2004-07-01), None
Li et al. STN Accession No. 2005:519249; Document No. 143:59681 Abstract of CN 15110024).
Experimental Organic Chemistry, James F. Norris, Published 1924, pp. 3 and 4.
Norris, 1924, Experimental Organic Chemistry, McGraw-Hill Book Company Inc. pp. 3).
A. Gravem, “A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients”, Acta Psychiatr. Scand. 1987, vol. 75, p. 478-486.

Affiliated with

Also associated with

Rating

Crystalline citalopram diol intermediate alkali does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystalline citalopram diol intermediate alkali, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline citalopram diol intermediate alkali will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4005918